Table 4.

Cancer-Specific Survival, ARB cohort

		Kaplan-Meier			Cox Univariable Analysis			Cox Multivariable Analysis
		CSS2 (%)	95%CI (%)	p (logrank)	HR	95%CI	p (class)	HR	95%CI	p (class)	p (variable)
Disease/Drug Category	D+ARB	77.9	74.1–81.2	0.026	-	-	-	-	-	-	0.107
	DnARB	73.4	71.7–75.0		1.29	1.06–1.57	0.010	1.23	1.00–1.50	0.050
	nD	74.8	71.8–77.6		1.18	0.94–1.47	0.150	1.11	0.86–1.42	0.426
Age	66–74	79.2	77.4–80.8	<0.001	-	-	-	-	-	-	<0.001
	75–84	71.7	69.2–74.0		1.45	1.27–1.66	<0.001	1.60	1.40–1.84	<0.001
	85+	59.0	54.4–63.3		2.34	1.99–2.75	<0.001	2.54	2.11–3.05	<0.001
Sex	Male	46.9	75.3–78.5	<0.001	-	-	-	-	-	-	0.002
	Female	69.1	66.6–71.5		1.42	1.26–1.61	<0.001	1.24	1.08–1.42	0.002
Race	White	75.5	74.0–77.0	<0.001	-	-	-	-	-	-	0.462
	Black	69.1	65.7–72.2		1.28	1.11–1.47	0.001	1.06	0.91–1.24	0.462
Marital Status	Married/Partnered	79.3	77.4–87.0	<0.001	-	-	-	-	-	-	0.001
	Non-Married	69.5	67.4–71.4		1.61	1.42–1.81	<0.001	1.25	1.10–1.43	0.001
Geographic Region	West	73.5	71.3–75.6	0.028	-	-	-	-	-	-	0.060
	East	78.0	74.9–80.8		0.83	0.69–0.98	0.032	0.77	0.63–0.94	0.009
	Midwest	74.9	70.8–78.5		0.97	0.80–1.19	0.792	0.97	0.78–1.21	0.803
	South	72.7	70.1–75.2		1.09	0.95–1.26	0.232	0.96	0.81–1.13	0.588
Population Density	Metropolitan	74.4	72.9–75.9	0.809	-	-	-	-	-	-	0.849
	Urban	73.6	70.2–76.6		1.05	0.90–1.22	0.551	1.12	0.74–1.68	0.592
	Rural	75.0	65.4–82.4		0.96	0.65–1.42	0.838	1.03	0.86–1.22	0.769
Year of Diagnosis	2008	73.9	69.7–77.6	0.515	-	-	-	-	-	-	0.247
	2009	72.8	68.7–76.5		1.05	0.83–1.34	0.673	1.05	0.82–1.34	0.693
	2010	71.2	67.0–74.9		1.11	0.87–1.40	0.410	1.08	0.85–1.37	0.542
	2011	74.7	70.9–78.0		0.97	0.76–1.23	0.794	0.86	0.67–1.09	0.216
	2012	73.9	70.2–77.2		0.99	0.78–1.25	0.932	0.94	0.74–1.19	0.614
	2013	75.6	72.1–78.7		0.92	0.72–1.16	0.458	0.96	0.76–1.21	0.715
	2014	77.0	73.0–80.5		0.91	0.72–1.16	0.454	0.85	0.67–1.09	0.202
	2015	89.6	85.8–92.4		0.81	0.57–1.14	0.219	0.76	0.53–1.08	0.126
Primary Site	Oral Cavity	70.7	67.7–73.4	<0.001	-	-	-	-	-	-	<0.001
	Lip	93.5	89.2–96.1		0.18	0.11–0.31	<0.001	0.26	0.15–0.45	<0.001
	Salivary Glands	73.3	64.2–80.3		0.87	0.61–1.25	0.460	0.63	0.43–0.91	0.013
	Oropharynx	73.6	70.7–76.2		0.91	0.78–1.08	0.278	0.58	0.48–0.71	<0.001
	Nasopharynx	72.0	59.8–81.1		0.96	0.61–1.51	0.869	0.58	0.36–0.93	0.024
	Hypopharynx	51.2	43.4–58.5		1.79	1.41–2.26	<0.001	0.96	0.73–1.25	0.743
	Larynx	79.2	76.8–81.3		0.69	0.58–0.81	<0.001	0.66	0.54–0.81	<0.001
	Overlapping/NOS	67.7	61.4–73.2		1.12	0.88–1.43	0.355	1.04	0.81–1.33	0.746
T-Classification	T0–1	88.9	87.1–90.5	<0.001	-	-	-	-	-	-	<0.001
	T2	73.5	70.8–76.1		2.57	2.12–3.12	<0.001	1.80	1.18–2.74	0.006
	T3	60.7	56.4–64.7		4.36	3.56–5.35	<0.001	4.03	2.60–6.24	<0.001
	T4	52.4	48.3–56.4		5.71	4.71–6.93	<0.001	5.04	3.33–7.63	<0.001
	Unknown	76.2	71.3–80.3		2.54	1.95–3.30	<0.001	4.12	2.44–6.97	<0.001
N-Classification	N0	78.5	81.4–84.4	<0.001	-	-	-	-	-	-	<0.001
	N1	76.4	57.5–65.7		2.59	2.20–3.05	<0.001	2.22	1.86–2.66	<0.001
	N2	67.9	57.6–63.9		2.65	2.31–3.04	<0.001	2.49	2.10–2.95	<0.001
	N3	62.2	42.1–64.6		3.41	2.44–4.77	<0.001	3.31	2.30–4.76	<0.001
Comorbidity Index	0	78.5	76.4–80.5	<0.001	-	-	-	-	-	-	<0.001
	1	76.4	73.8–78.8		1.12	0.96–1.32	0.153	1.15	0.97–1.37	0.108
	2	67.9	65.2–70.4		1.65	1.43–1.90	<0.001	1.69	1.43–2.01	<0.001
	Unknown	62.2	51.1–71.5		2.02	1.42–2.87	<0.001	1.13	0.78–1.66	0.517
Facility Type	Other	73.8	71.7–75.8	0.235	-	-	-	-	-	-	0.093
	NCI Center	76.4	72.6–79.8		0.85	0.71–1.04	0.108	0.81	0.66–0.99	0.040
	Teaching Hospital	74.0	71.9–76.0		1.00	0.88–1.13	0.971	0.99	0.87–1.14	0.940
Tract % High School Only	≤ median	76.0	74.1–77.8	0.005	-	-	-	-	-	-	0.062
	> median	72.6	70.6–74.5		1.19	1.05–1.34	0.005	1.15	0.99–1.34	0.062
Tract % Below Poverty	≤ median	77.2	75.3–79.0	<0.001	-	-	-	-	-	-	0.137
	> median	71.4	69.4–73.3		1.31	1.17–1.48	<0.001	1.11	0.97–1.28	0.137
Surgery	No	70.4	68.4–72.3	<0.001	-	-	-	-	-	-	<0.001
	Yes	78.6	76.7–80.4		0.66	0.58–0.74	<0.001	0.64	0.54–0.75	<0.001
Chemotherapy	No	80.4	78.8–82.0	<0.001	-	-	-	-	-	-	0.653
	Yes	65.6	63.2–67.8		1.84	1.63–2.08	<0.001	1.04	0.88–1.22	0.653
Radiotherapy	No	82.0	79.7–84.1	<0.001	-	-	-	-	-	-	<0.001
	Yes	71.3	69.7–73.0		1.60	1.38–1.85	<0.001	0.54	0.40–0.74	<0.001
ACEi	No	73.4	71.8–75.0	0.012	-	-	-	-	-	-	0.332
	Yes	76.7	74.1–79.2		0.84	0.73–0.96	0.013	0.93	0.80–1.08	0.332
Statin	No	71.4	69.5–73.2	0.016	-	-	-	-	-	-	<0.001
	Yes	78.4	76.4–80.3		0.70	0.62–0.80	<0.001	0.76	0.66–0.88	<0.001
Fibrate	No	74.1	72.7–75.5	<0.001	-	-	-	-	-	-	0.963
	Yes	78.2	69.9–84.5		0.77	0.54–1.12	0.173	1.01	0.69–1.47	0.963
Metformin	No	73.9	72.4–75.3	0.168	-	-	-	-	-	-	0.372
	Yes	78.0	73.5–81.8		0.77	0.62–0.96	0.019	0.89	0.70–1.14	0.372
DLD	No	69.7	67.1–72.2	0.018	-	-	-	-	-	-	0.100
	Yes	76.4	74.8–78.0		0.75	0.67–0.85	<0.001	0.89	0.77–1.02	0.100
DM	No	74.3	72.6–75.9	0.799	-	-	-	-	-	-	0.305
	Yes	74.2	71.7–76.5		1.00	0.88–1.14	0.999	0.92	0.78–1.08	0.305

Please refer to Supplemental Table 2 for size of group depicted in each row.

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CSS2, cancer-specific survival at two years; D+ARB; disease and taking ARB; DnARB, disease and not taking ARB; DLD, dyslipidemia; DM, diabetes mellitus; HR, hazard ratio; NCI, National Cancer Institute; nD, no disease; NOS, not otherwise specified; 95%CI, 95% confidence interval